AN2 Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-03-30: Study NCT07301320; Company role Collaborator; Phase Phase 2; Status Recruiting.
- 2025-08-04: Study NCT07024589; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2023-11-01: Study NCT06089668; Company role Lead sponsor; Phase Observational; Status Completed.
- 2023-06-05: Study NCT05995444; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | NCT07301320 Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | Collaborator Lead: Kevin Winthrop | Phase 2 | Recruiting | Mycobacterium Abscessus Infection | 84 | 2028-05 |
| 2025-08-04 | NCT07024589 First-in-Human Trial of Oral AN2-502998 | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 72 | 2026-03-14 |
| 2023-11-01 | NCT06089668 An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis | Lead sponsor | Observational | Completed | Melioidosis | 200 | 2025-02-02 |
| 2023-06-05 | NCT05995444 A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 24 | 2023-08-03 |
| 2022-05-20 | NCT05327803 Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | Lead sponsor | Phase 2, Phase 3 | Terminated Results posted | MAC Lung Disease; Treatment Refractory MAC Lung Disease | 177 | 2024-12-18 |
| 2022-02-21 | NCT05283746 A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function | Lead sponsor | Phase 1 | Completed | Renal Insufficiency | 40 | 2022-06-27 |
| 2021-06-10 | NCT04892641 Phase 1 Study of Epetraborole Tablets | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 51 | 2022-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |